PRMT5 and neoplasm: Combination therapy demonstrated activity in vivo, since MSI2 depletion resulted in a 50% reduction of tumor growth which was further reduced with the addition of PRMT5 inhibitor (80% drop) without inducing toxicity (Fig. 3H and Supplementary Fig. 3E).